<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04504721</url>
  </required_header>
  <id_info>
    <org_study_id>N202003152</org_study_id>
    <nct_id>NCT04504721</nct_id>
  </id_info>
  <brief_title>Effects of Blue-enriched White Light Therapy in Patients With Fibromyalgia</brief_title>
  <official_title>Effects of Blue-enriched White Light Therapy on Sleep Quality, Depression, Psychomotor Vigilance, and Symptom Severity in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is a chronic condition with an unclear etiology. The syndrome includes symptoms&#xD;
      such as chronic musculoskeletal pain, cognitive dysfunctions, fatigue, sleep disorders, and&#xD;
      circadian rhythm disturbances. Fibromyalgia-related pain is associated with a substantial&#xD;
      socioeconomic burden including greater health care costs and productivity loss from work.&#xD;
      Light therapy can improve sleep quality and sleep architecture, advance sleep phases and&#xD;
      reduce pain sensitivity and that the effect of light therapy on mood and cognitive function&#xD;
      have been widely supported.This randomized controlled study aims to examine the effects of&#xD;
      light therapy on sleep quality, depressive symptoms, psychomotor vigilance performance, and&#xD;
      overall symptom severity in patients with fibromyalgia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia is a central sensitivity syndrome characterized by chronic widespread pain,&#xD;
      cognitive dysfunctions, fatigue, sleep disorders, and circadian dysregulation. Light therapy&#xD;
      can improve sleep quality and sleep architecture, advance sleep phases and reduce pain&#xD;
      sensitivity and that the effect of light therapy on mood and cognitive function have been&#xD;
      widely supported, research into the effect of light therapy for patients with fibromyalgia&#xD;
      who often suffer from sleep and mood disturbance, pain, and cognitive impairments is of both&#xD;
      research interest and therapeutic implications. This study will use a randomized, parallel&#xD;
      group, assessor-blind, waiting-list controlled trial design. The primary outcome is symptom&#xD;
      severity. The secondary outcomes include: sleep quality; depressive symptoms; psychomotor&#xD;
      vigilance and attention; and sleep phase changes. The intervention will take 8 weeks with 30&#xD;
      minutes exposure at awakening to blue-enriched white light. A total of 80 participants, aged&#xD;
      20 to 64, with a diagnosis of fibromyalgia will be enrolled and randomly assigned into one of&#xD;
      the two parallel groups: an intervention and a waiting list group. For the intervention&#xD;
      group, outcomes will be assessed at baseline, immediately after, and 2 months after the&#xD;
      8-week intervention period. For the waiting list group, outcomes will be assessed at&#xD;
      baseline, immediately after the 8-week waiting period, and 2 months after the intervention&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire-Revised Version</measure>
    <time_frame>Baseline</time_frame>
    <description>Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire-Revised Version</measure>
    <time_frame>Immediately after the 8-week intervention period</time_frame>
    <description>Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire-Revised Version</measure>
    <time_frame>2 months after the 8-week intervention period</time_frame>
    <description>Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Immediately after the 8-week intervention period</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>2 months after the 8-week intervention period</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>Immediately after the 8-week intervention period</time_frame>
    <description>The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>2 months after the 8-week intervention period</time_frame>
    <description>The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor vigilance and attention</measure>
    <time_frame>Baseline</time_frame>
    <description>Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor vigilance and attention</measure>
    <time_frame>Immediately after the 8-week intervention period</time_frame>
    <description>Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor vigilance and attention</measure>
    <time_frame>2 months after the 8-week intervention period</time_frame>
    <description>Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep phase assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep phase assessment</measure>
    <time_frame>Immediately after the 8-week intervention period</time_frame>
    <description>The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep phase assessment</measure>
    <time_frame>2 months after the 8-week intervention period</time_frame>
    <description>The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Light therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waiting list group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>light therapy</intervention_name>
    <description>The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.</description>
    <arm_group_label>Light therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be aged from 20 to 64 years old.&#xD;
&#xD;
          2. Participants must read and understand Chinese language.&#xD;
&#xD;
          3. Participants must be outpatients.&#xD;
&#xD;
          4. Participants must have a confirmed diagnosis of fibromyalgia according to the 2016&#xD;
             American College of Rheumatology diagnostic criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are admitted to the hospital.&#xD;
&#xD;
          2. Subjects who have other significant chronic disease, past or present psychosis, or&#xD;
             bipolar disorder.&#xD;
&#xD;
          3. Subjects who have ophthalmic pathology (cataract, macular degeneration, glaucoma,&#xD;
             retinitis pigmentosa), eye surgery, diseases affecting the retina (retinopathy,&#xD;
             diabetes, herpes, etc.), color blind, or taking photosensitizing medications.&#xD;
&#xD;
          4. Subjects who are taking opiates or benzodiazepines.&#xD;
&#xD;
          5. Subjects who work night shifts, or travel across more than two time zones in the month&#xD;
             prior to enrolling in the study.&#xD;
&#xD;
          6. Subjects who are pregnant.&#xD;
&#xD;
          7. Subjects who have used light treatment in the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Shan Tsai, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Taipei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bio-Behavior Research Laboratory</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>April 11, 2023</last_update_submitted>
  <last_update_submitted_qc>April 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University</investigator_affiliation>
    <investigator_full_name>Pei-Shan, Tsai</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Light therapy</keyword>
  <keyword>Sleep quality</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04504721
org study id: N202003152
nct id: NCT04504721
lead sponsor: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
Fibromyalgia is a chronic condition with an unclear etiology. The syndrome includes symptoms
      such as chronic musculoskeletal pain, cognitive dysfunctions, fatigue, sleep disorders, and
      circadian rhythm disturbances. Fibromyalgia-related pain is associated with a substantial
      socioeconomic burden including greater health care costs and productivity loss from work.
      Light therapy can improve sleep quality and sleep architecture, advance sleep phases and
      reduce pain sensitivity and that the effect of light therapy on mood and cognitive function
      have been widely supported.This randomized controlled study aims to examine the effects of
      light therapy on sleep quality, depressive symptoms, psychomotor vigilance performance, and
      overall symptom severity in patients with fibromyalgia.
Fibromyalgia is a central sensitivity syndrome characterized by chronic widespread pain,
      cognitive dysfunctions, fatigue, sleep disorders, and circadian dysregulation. Light therapy
      can improve sleep quality and sleep architecture, advance sleep phases and reduce pain
      sensitivity and that the effect of light therapy on mood and cognitive function have been
      widely supported, research into the effect of light therapy for patients with fibromyalgia
      who often suffer from sleep and mood disturbance, pain, and cognitive impairments is of both
      research interest and therapeutic implications. This study will use a randomized, parallel
      group, assessor-blind, waiting-list controlled trial design. The primary outcome is symptom
      severity. The secondary outcomes include: sleep quality; depressive symptoms; psychomotor
      vigilance and attention; and sleep phase changes. The intervention will take 8 weeks with 30
      minutes exposure at awakening to blue-enriched white light. A total of 80 participants, aged
      20 to 64, with a diagnosis of fibromyalgia will be enrolled and randomly assigned into one of
      the two parallel groups: an intervention and a waiting list group. For the intervention
      group, outcomes will be assessed at baseline, immediately after, and 2 months after the
      8-week intervention period. For the waiting list group, outcomes will be assessed at
      baseline, immediately after the 8-week waiting period, and 2 months after the intervention
      period.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: Single (Participant)
measure: Fibromyalgia Impact Questionnaire-Revised Version
time frame: Baseline
description: Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.
measure: Fibromyalgia Impact Questionnaire-Revised Version
time frame: Immediately after the 8-week intervention period
description: Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.
measure: Fibromyalgia Impact Questionnaire-Revised Version
time frame: 2 months after the 8-week intervention period
description: Fibromyalgia symptom severity will be measured using the Fibromyalgia Impact Questionnaire-Revised Version (FIQR) .The FIQR contains a total of 21 individual questions in three domains: function, impact and symptom domains. All questions are based on an 11-point numeric rating scale of 0 to 10, with '0' representing 'no difficulty' and '10' representing 'worst'.
measure: Sleep quality
time frame: Baseline
description: The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.
measure: Sleep quality
time frame: Immediately after the 8-week intervention period
description: The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.
measure: Sleep quality
time frame: 2 months after the 8-week intervention period
description: The Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire that assesses sleep quality over a 1-month time interval. The seven components include subjective sleep quality, sleep latency, total sleep time, habitual sleep efficiency, sleep disorders, use of sleep medications, and daytime dysfunction. All questions are scored on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where higher scores denote a poorer sleep quality.
measure: Depressive symptoms
time frame: Baseline
description: The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.
measure: Depressive symptoms
time frame: Immediately after the 8-week intervention period
description: The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.
measure: Depressive symptoms
time frame: 2 months after the 8-week intervention period
description: The Beck Depression Inventory Version 2 (BDI-II) is a self-report 21-item questionnaire in which responses are rated on a 0 to 3 interval scale, with a higher score denoting mire frequent symptoms. The possible score of BDI-II ranges from 0 to 63, with higher scores representing more sever ratings of depression.
measure: Psychomotor vigilance and attention
time frame: Baseline
description: Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.
measure: Psychomotor vigilance and attention
time frame: Immediately after the 8-week intervention period
description: Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.
measure: Psychomotor vigilance and attention
time frame: 2 months after the 8-week intervention period
description: Psychomotor vigilance and attention will be measured using the Psychomotor Vigilance Task (PVT). The visual stimulus and performance feedback are presented on the device.
measure: Sleep phase assessment
time frame: Baseline
description: The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.
measure: Sleep phase assessment
time frame: Immediately after the 8-week intervention period
description: The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.
measure: Sleep phase assessment
time frame: 2 months after the 8-week intervention period
description: The Morningness-Eveningness Questionnaire (MEQ) is used to estimate phase preferences in circadian rhythms based on participants' self-descriptions. timing. Questions evaluate the time that individuals get up and go to bed, self-reported preferred times for physical and mental activity, and also the individual's subjective alertness. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing.
arm group label: Light therapy group
arm group type: Experimental
description: The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
arm group label: Waiting list group
arm group type: No Intervention
description: Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
intervention type: Other
intervention name: light therapy
description: The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
arm group label: Light therapy group
criteria: 
gender: All
minimum age: 20 Years
maximum age: 64 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Pei-Shan Tsai, PhD
role: Study Chair
affiliation: Taipei Medical University
facility: 
country: Taiwan
responsible party type: Principal Investigator
investigator affiliation: Taipei Medical University
investigator full name: Pei-Shan, Tsai
investigator title: Principal Investigator
mesh term: Fibromyalgia
mesh term: Myofascial Pain Syndromes
sharing ipd: No